Summary
25.68 -0.24(-0.93%)07/05/2024
Royalty Pharma plc (RPRX)
Royalty Pharma plc (RPRX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.08 | -2.64 | -4.85 | -12.10 | -6.52 | -15.47 | 0.00 | -40.35 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 25.68 | |
| Open | 25.84 | |
| High | 25.86 | |
| Low | 25.43 | |
| Volume | 1,640,832 | |
| Change | -0.28 | |
| Change % | -1.08 | |
| Avg Volume (20 Days) | 1,842,500 | |
| Volume/Avg Volume (20 Days) Ratio | 0.89 | |
| 52 Week Range | 25.43 - 31.66 | |
| Price vs 52 Week High | -18.89% | |
| Price vs 52 Week Low | 0.98% | |
| Range | -0.62 | |
| Gap Up/Down | -0.52 | |
Fundamentals | ||
| Market Capitalization (Mln) | 11,606 | |
| EBIDTA | 1,679,401,984 | |
| PE Ratio | 19.4964 | |
| PEG Ratio | -0.0200 | |
| WallStreet Target Price | 51.43 | |
| Book Value | 13.4880 | |
| Earnings Per Share | 1.9260 | |
| EPS Estimate Current Quarter | 0.6900 | |
| EPS Estimate Next Quarter | 0.7500 | |
| EPS Estimate Current Year | 2.8300 | |
| EPS Estimate Next Year | 3.1700 | |
| Diluted EPS (TTM) | 1.9260 | |
| Revenues | ||
| Profit Marging | 0.3425 | |
| Operating Marging (TTM) | 0.7246 | |
| Return on asset (TTM) | 0.0614 | |
| Return on equity (TTM) | 0.1540 | |
| Revenue TTM | 2,285,905,920 | |
| Revenue per share TTM | 5.6220 | |
| Quarterly Revenue Growth (YOY) | 0.0880 | |
| Quarterly Earnings Growth (YOY) | -0.6970 | |
| Gross Profit (TTM) | 1,891,514,000 | |
| Dividends | ||
| Dividend Share | 0.6600 | |
| Dividend Yield | 0.0174 | |
| Valuations | ||
| Trailing PE | 19.4964 | |
| Forward PE | 11.6009 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.8004 | |
| Revenue Enterprise Value | 9.0205 | |
| EBITDA Enterprise Value | 11.8904 | |
| Shares | ||
| Shares Outstanding | 429,511,008 | |
| Shares Float | 322,618,608 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 16.30 | |
| Institutions (%) | 62.00 | |
06/26 06:00 EST - investorplace.com
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
I'm on the hunt for ‘Strong Buy' biotech stocks. According to Finviz.com, there are 680 U.S.-listed biotech stocks.
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
I'm on the hunt for ‘Strong Buy' biotech stocks. According to Finviz.com, there are 680 U.S.-listed biotech stocks.
06/24 12:56 EST - investorplace.com
7 Biotech Stocks to Buy on the Dip: June 2024
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it's important to save money and invest for the future.
7 Biotech Stocks to Buy on the Dip: June 2024
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it's important to save money and invest for the future.
06/12 09:15 EST - benzinga.com
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
06/05 06:14 EST - investorplace.com
June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Wall Street regards the healthcare sector as a constant source of innovation, while biotechnology stands at the pinnacle of groundbreaking medical advancements. The long-term potential of robust biotech stocks to buy remains undeniable for investors.
June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Wall Street regards the healthcare sector as a constant source of innovation, while biotechnology stands at the pinnacle of groundbreaking medical advancements. The long-term potential of robust biotech stocks to buy remains undeniable for investors.
06/04 16:15 EST - globenewswire.com
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pharma's “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days.
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pharma's “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days.
06/03 17:15 EST - globenewswire.com
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”):
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”):
05/28 07:10 EST - globenewswire.com
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an interest in Agios Pharmaceuticals' royalty on Servier's vorasidenib for $905 million in upfront cash contingent on U.S. Food and Drug Administration (FDA) approval of vorasidenib.
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an interest in Agios Pharmaceuticals' royalty on Servier's vorasidenib for $905 million in upfront cash contingent on U.S. Food and Drug Administration (FDA) approval of vorasidenib.
05/22 16:10 EST - globenewswire.com
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company's expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed specialty cardiology business.
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company's expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed specialty cardiology business.
05/20 14:41 EST - investorplace.com
7 Dividend Stocks to Buy at a 52-Week Low
On the search for high-quality stocks at low prices? Consider taking a look at dividend stocks at a 52-week low.
7 Dividend Stocks to Buy at a 52-Week Low
On the search for high-quality stocks at low prices? Consider taking a look at dividend stocks at a 52-week low.
05/13 08:15 EST - globenewswire.com
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
05/09 13:32 EST - seekingalpha.com
Royalty Pharma PLC (RPRX) Q1 2024 Earnings Call Transcript
Royalty Pharma PLC (NASDAQ:RPRX ) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants George Grofik - Senior Vice President & Head of Investor Relations & Communications Pablo Legorreta - Founder, Chairman & Chief Executive Officer Marshall Urist - Executive Vice President & Head, Research & Investments Chris Hite - Vice Chairman & Executive Vice President Terrance Coyne - Executive Vice President & Chief Financial Officer Conference Call Participants Chris Shibutani - Goldman Sachs Geoff Meacham - Bank of America Peter Verdult - Citi Michael DiFiore - Evercore Steve Scala - TD Cowen Operator Ladies and gentlemen, thank you for standing by. Welcome to Royalty Pharma First Quarter 2024 Earnings Conference Call.
Royalty Pharma PLC (RPRX) Q1 2024 Earnings Call Transcript
Royalty Pharma PLC (NASDAQ:RPRX ) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants George Grofik - Senior Vice President & Head of Investor Relations & Communications Pablo Legorreta - Founder, Chairman & Chief Executive Officer Marshall Urist - Executive Vice President & Head, Research & Investments Chris Hite - Vice Chairman & Executive Vice President Terrance Coyne - Executive Vice President & Chief Financial Officer Conference Call Participants Chris Shibutani - Goldman Sachs Geoff Meacham - Bank of America Peter Verdult - Citi Michael DiFiore - Evercore Steve Scala - TD Cowen Operator Ladies and gentlemen, thank you for standing by. Welcome to Royalty Pharma First Quarter 2024 Earnings Conference Call.
05/09 13:01 EST - zacks.com
Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
05/09 09:10 EST - zacks.com
Royalty Pharma (RPRX) Beats Q1 Earnings and Revenue Estimates
Royalty Pharma (RPRX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.60 per share a year ago.
Royalty Pharma (RPRX) Beats Q1 Earnings and Revenue Estimates
Royalty Pharma (RPRX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.60 per share a year ago.
05/09 06:45 EST - globenewswire.com
Royalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it will acquire royalties and milestones on frexalimab owned by ImmuNext, Inc. (ImmuNext) for approximately $525 million in cash including estimated transaction costs. ImmuNext, a privately-held biotechnology company, is entitled to a royalty on net sales of frexalimab and milestones related to the achievement of regulatory and clinical events and commercial sales.
Royalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it will acquire royalties and milestones on frexalimab owned by ImmuNext, Inc. (ImmuNext) for approximately $525 million in cash including estimated transaction costs. ImmuNext, a privately-held biotechnology company, is entitled to a royalty on net sales of frexalimab and milestones related to the achievement of regulatory and clinical events and commercial sales.
05/08 09:56 EST - zacks.com
Why Earnings Season Could Be Great for Royalty Pharma (RPRX)
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Earnings Season Could Be Great for Royalty Pharma (RPRX)
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
05/06 10:21 EST - zacks.com
Insights Into Royalty Pharma (RPRX) Q1: Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Royalty Pharma (RPRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Insights Into Royalty Pharma (RPRX) Q1: Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Royalty Pharma (RPRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
05/02 11:06 EST - zacks.com
Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/19 08:15 EST - globenewswire.com
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
04/17 08:15 EST - globenewswire.com
Royalty Pharma Declares Second Quarter 2024 Dividend
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share.
Royalty Pharma Declares Second Quarter 2024 Dividend
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share.
04/11 14:10 EST - investorplace.com
3 Pharma Stocks to Sell in April Before They Crash & Burn
There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures.
3 Pharma Stocks to Sell in April Before They Crash & Burn
There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures.